Announcement on the 8th of March said:
"The trial’s Principal Investigator, Professor Jeffrey Lancet, M.D., said “the trial is proceeding well to date, with no significant safety issues, along with some early signals of efficacy. We’re looking forward to the next stage of dose escalation.”"
Fingers crossed for most importantly the patients and shareholders too.
